Search - tctmd.com

Displaying 21 - 40 of 150

Sort: Relevancy | Date

December 2022 News Roundup

News Opinion CV Team Dispatch

December 2022 News Roundup

December 28, 2022

A Simple Nudge Moves the Needle on Statin Prescribing

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock

News Conference News AHA 2022

Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock

November 06, 2022

Cardiac Biomarkers Reflect Sex Hormones in Transgender People

News Daily News

Cardiac Biomarkers Reflect Sex Hormones in Transgender People

October 06, 2022

Bloodlines: How Far Should Cardiologists Go in Treating Family?

News Features

Bloodlines: How Far Should Cardiologists Go in Treating Family?

March 10, 2022

SCAI SHOCK: Update Refines Cardiogenic Shock Classification

News Daily News

SCAI SHOCK: Update Refines Cardiogenic Shock Classification

January 31, 2022

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

News Daily News

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Michael O'Riordan

December 09, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

News Conference News TCT 2021

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

November 11, 2021

Cardiogenic Shock: SCAI Categories Get a Rethink as Research Rolls On

News Conference News TCT 2021

Cardiogenic Shock: SCAI Categories Get a Rethink as Research Rolls On

November 09, 2021

COVID-19: TCTMD’s Dispatch for November Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 2

November 08, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

EXPLANT-TAVR: Data Spur Conversation About Balancing Risk and Lifetime Management

News Daily News

EXPLANT-TAVR: Data Spur Conversation About Balancing Risk and Lifetime Management

September 22, 2021

To Increase Physical Activity, Put Patients In Charge and Make It a Game

News Daily News

To Increase Physical Activity, Put Patients In Charge and Make It a Game

Yael L. Maxwell

September 07, 2021

News Daily News

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

Alexandra Dangas

September 06, 2021

New CV Surgery Guidelines Shift Focus to ‘Blood Management’

News Daily News

CV Surgery Societies Urge Shift to ‘Blood Management’

Yael L. Maxwell

June 30, 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

News Conference News ACC 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

Michael O'Riordan

May 15, 2021

Surgery After Failed Mitral Edge-to-Edge Repair Tends to Be Replacement

News Daily News

Surgery After Failed Mitral Edge-to-Edge Repair Tends to Be Replacement

May 05, 2021

New NACMI COVID-19 Numbers Highlight Quality Care, Sobering Reality

News Conference News SCAI 2021

New NACMI COVID-19 Numbers Highlight Quality Care, Sobering Reality

April 28, 2021

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

News Daily News

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

April 22, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.